

ARGINASE1 POLYPEPTIDES

Field of the Invention

The present invention relates to novel polypeptides, which are derived from Arginase

5 1. The invention also relates to polynucleotides encoding the polypeptides. The invention also relates to compositions comprising the polypeptides and polynucleotides. The invention also concerns uses of the polypeptides, polynucleotides, and compositions.

Background of the Invention

10 Arginase is an enzyme that catalyses a reaction which converts the amino acid L-arginine into L-ornithine and urea. This depletes the microenvironment of arginine and leads to a suppression of tumor- specific cytotoxic T-cell responses. Increased Arginase activity has been detected in the cancer cells of patients with breast, lung, colon or prostate cancer. It has been shown both in vitro and in vivo that mouse macrophages transfected with a rat

15 Arginase gene promote the proliferation of co-cultured tumour cells. Furthermore induction of Arginase expression by macrophages has been shown to increase tumour vascularization through polyamine synthesis. The results of a murine lung carcinoma model showed that there existed a subpopulation of mature tumor-associated myeloid cells that expressed high levels of Arginase. These tumor-associated myeloid cells depleted the extracellular L-

20 Arginine which inhibited antigen-specific proliferation of the tumor infiltrating lymphocytes (TILs). Injection of an Arginase inhibitor blocked the growth of the lung carcinoma in the mice. This shows how induction of Arginase expression in tumor cells and tumor associated myeloid cells might promote tumor growth by suppression of the anti- tumor immune responses through negative effects on TILs.

25 MDSCs (myeloid-derived suppressor cells) inhibit the activation, proliferation, and cytotoxicity of effector T cells and natural killer cells, as well as induce Treg differentiation and expansion. Both cancer cells and MDSCs can suppress T cells by manipulating L-arginine metabolism via the enzymes nitric-oxide synthase (NOS) and arginase. Many tumours exhibit increased expressions of arginase and inducible NOS (iNOS), leading to

30 arginine depletion from the tumour microenvironment. Several studies emphasize the importance of this altered tumour arginine metabolism in the suppression of tumour-specific T-cell responses, and it was recently demonstrated that Acute Myeloid Leukemia (AML) blasts show an arginase-dependent ability to inhibit T-cell proliferation and hematopoietic

stem cells. Furthermore, arginase and iNOS inhibitors reduce the suppressive activity of AML.

Summary of the invention

5 The present inventors have previously identified a 50 amino acid region of Arginase 1 which is a “hot spot” for immunogenicity. This region corresponds to positions 161-210 of full length human Arginase 1 (SEQ ID NO: 10). The region and peptides derived from it are described in WO2018065563. (Note that the terms “*Arginase I*”, “*ArgI*”, “*ArginaseI*” are used interchangeably herein).

10 The present inventors have now identified that a specific sub-set of polypeptides derived from this region are particularly effective at stimulating immune responses. The polypeptides of the present invention are thus expected to be particularly effective at stimulating a beneficial immune response against Arginase 1 and Arginase 1-expressing cells. The development of novel immune therapies for cancer requires a thorough understanding of
15 the molecules that are involved in the pathogenesis as well as the specific proteins recognized by the immune system. In the clinical setting the induction of Arginase specific immune responses could in addition to the killing of cancer cells support anti-cancer immune responses in general by suppressing the immune suppressive function of Arginase expressing cells especially MDSC and tumor-associated macrophages (TAMs). Hence, since Arginase-
20 expressing cells antagonize the desired effects of other immunotherapeutic approaches targeting myeloid dendritic cells e.g. by vaccination with the polypeptides of the present invention, would consequently be highly synergistic with additional anti-cancer immunotherapy.

The present invention provides:

- 25 An isolated polypeptide consisting of any one of the following amino acid sequences:
- a. ISAKDIVYIGLRDVPGEHYILKTLGIKYFSMTEVDRL (SEQ ID NO:1);
 - b. ISAKDIVYIGLRDVPGEHYIIKTLGIKYFSMTEVDKL (SEQ ID NO: 2);
 - c. ISAKDIVYIGLRDVPGEHYILKTLGIKYFSM (SEQ ID NO:3);
 - d. ISAKDIVYIGLRDVPGEHYIIKTLGIKYFSM (SEQ ID NO:4);
 - 30 e. ISAKDIVYIGLRDVPGEHYILKTLGIKYFSMTEVDRLGIGK (SEQ ID NO:5);
 - f. ISAKDIVYIGLRDVPGEHYIIKTLGIKYFSMTEVDKLGIGK (SEQ ID NO:6).

The present invention provides a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.

Disclosed herein is a polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.

5 The present invention further provides a polynucleotide encoding a polypeptide of the invention, optionally comprised within a vector.

Disclosed herein is a polynucleotide encoding the polypeptide as defined herein.

Disclosed herein is a vector comprising the polynucleotide as defined herein.

10 The present invention also provides a composition comprising a polypeptide or polynucleotide of the invention, at least one pharmaceutically acceptable diluent, carrier or preservative, and optionally an adjuvant.

Disclosed herein is a composition comprising the polynucleotide as defined herein and an adjuvant.

15 Disclosed herein is a composition comprising the polypeptide as defined herein, or the vector as defined herein, and an adjuvant.

The present invention also provides a method of treating or preventing a disease or condition in a subject, the method comprising administering to the subject a polypeptide, polynucleotide, or a composition of the invention.

20 The present invention provides a polypeptide or polynucleotide of the invention or the composition of the invention for use in a method of treating or preventing a disease or condition in a subject, wherein said polypeptide or polynucleotide or said composition is to be administered to the subject.

25 Disclosed herein is the polypeptide as defined herein, the vector as defined herein, or the composition as defined herein for use in a method of treating or preventing a disease or condition in a subject, wherein said polypeptide or vector or said composition is to be administered to the subject.

The present invention also provides a method of stimulating arginase1-specific T cells, the method comprising contacting the cells with a polypeptide, polynucleotide or composition of the invention, wherein the method is performed *ex vivo*.

30 Disclosed herein is a method of stimulating Arginase1-specific T cells, the method comprising contacting peripheral blood mononuclear cells (PBMCs) with the polypeptide as defined herein, the vector as defined herein, or the composition as defined herein, wherein the method is performed *ex vivo*.

The present invention also provides the use of a polypeptide, polynucleotide or composition of the invention in the manufacture of a medicament for the treatment or prevention of cancer in a subject.

Disclosed herein is the use of the polypeptide as defined herein, the vector as defined herein or the composition as defined herein in the manufacture of a medicament for the treatment or prevention of cancer in a subject.

Brief Description of the Figures

FIGURE 1 shows responses against long Arg1-derived peptides

IFN γ ELISPOT responses against ArgLong, ArgLong2 and ArgLong3 peptides in PBMCs from four healthy donors (HD). Bars represent the mean number of spots per well + standard error of the mean. Corresponding ELISPOT well images with and without the addition of peptides are also shown for each donor. Experiments were performed with 5×10^5 PBMCs/well in triplicates. TNTC- too numerous to count. * - $p \leq 0.05$ according to the distribution free resampling (DFR) rule.

FIGURE 2 shows responses against ArgLong2 compared to 20-mer peptides

IFN γ ELISPOT responses against Arg₁₇₁₋₁₉₀, Arg₁₈₁₋₂₀₀, Arg₁₉₁₋₂₁₀ and ArgLong2 in 19 healthy donors (top) and 16 cancer patients (bottom). Each dot represents an average number of peptide specific spots for a single patient/donor. Responses were calculated by subtracting the average spot count in control wells from the average spot count in peptide stimulated wells. Experiments performed with $4.5-5 \times 10^5$ PBMCs/well for healthy donors and $2.2-5 \times 10^5$ PBMCs/well for cancer patients, in triplicates or duplicates. Responses against ArgLong2 were too numerous to count (TNTC) in six healthy donors and 2 cancer patients and set to be >500 spots.

FIGURE 3 shows CD4+ and CD8+ T cells respond to ArgLong2 *in vitro* and *ex vivo*

3A – *In vitro* responses against ArgLong2 in CD4+ (left) and CD8+ (right) T cells in intracellular staining of PBMCs from two healthy donors and one breast cancer patient. PBMCs were stimulated with ArgLong2 and low dose IL-2 for one week prior to ELISPOT assay.

3B – *Ex vivo* responses against ArgLong2 in CD4+ (left) and CD8+ (right) T cells in intracellular staining of PBMCs from two cancer patients, without prior stimulation (BC-breast cancer, MM-malignant melanoma).

5 **FIGURE 4 shows ArgLong2 specific CD4+ and CD8+ cells are memory T cells**

4A – *Ex vivo* responses against ArgLong2 in four healthy donors (HD) and two cancer patients (BC-breast cancer, MM-malignant melanoma). Experiment performed in triplicates with $1-5 \times 10^5$ cells/well.

10 **4B** – *Ex vivo* IFN γ ELISPOT of sorted CD4+ memory T cells (CD45RO+) from PBMCs of four healthy donors and two cancer patients (breast cancer and malignant melanoma). Experiment performed in triplicates with $1-3 \times 10^5$ cells/well.

4C – *Ex vivo* IFN γ ELISPOT of sorted CD8+ memory T cells (CD45RO+) from PBMCs of two healthy donors. Experiment performed in duplicates or singlets with 1×10^5 cells/well. Bars represent average spot counts in peptide stimulated and controls wells +SEM.

15

FIGURE 5 shows IL-4 stimulation activates ArgLong2 specific T cells

A – IFN γ ELISPOT for ArgLong2 responses in melanoma patient PBMCs stimulated with IL-4 and/or IL-2 for one week. Non-stimulated PBMCs used as control. Superimposed bars show the mean spot counts of control and peptide stimulated wells + SEM. Experiment
20 performed in triplicates with 3×10^5 cells/well. **B** – ArgLong2 specific responses in PBMCs from six healthy donors (HD) and two cancer patients (BC – breast cancer, MM – malignant melanoma) after stimulation with IL-2 (120U/ml) or IL-4 (100U/ml) for one week. Cells without cytokine stimulation used as control. Responses calculated as the difference in mean spot counts between peptide stimulated and control wells in ELISPOT. Experiment
25 performed in triplicates or duplicates with 3×10^5 cells/well.

FIGURE 6 shows ArgLong2-specific IFN γ immune responses mounted *in vivo* after immunization

Four mice were vaccinated with ArgLong2 peptide and the immune response developed
30 against the peptide was evaluated after 7 days by IFN γ ELISPOT. Cells from the spleen and draining lymph nodes from individual mice were subjected to ELISPOT assay. Bars represent the mean number of spots. ELISPOT were performed in triplicates with and

without addition of the ArgLong2 peptide. “*TNTC*” denotes too numerous to count. ** denotes $p < 0.01$ according to the distribution-free resampling method (DFR).

FIGURE 7 shows ArgLong2 vaccination induces anti-tumour effects in the MC38 colon adenocarcinoma tumour model

0.5×10⁶ MC38 tumour cells were inoculated subcutaneously on the right flank of 30 mice on day 0. On the same day vaccinations were initiated. The 15 mice in the treatment group were treated with 100 µg of ArgLong2 in emulsion with Montanide, and the 15 mice in the control group were treated with H₂O in emulsion with Montanide. $p = 0.030$ according to the Mixed effects analysis.

FIGURE 8 shows ArgLong2 vaccination induces anti-tumour effects in the B16F10 melanoma tumour model

0.5×10⁶ B16F10 tumour cells were inoculated subcutaneously on the right flank of 30 mice on day 0. On the same day vaccinations were initiated. The 15 mice in the treatment group were treated with 100 µg of ArgLong2 in emulsion with Montanide, and the 15 mice in the control group were treated with H₂O in emulsion with Montanide. After three vaccinations the treatment were stopped. Mice were euthanized when the tumour volume exceeded 864 mm³.

FIGURE 9 shows ArgLong2-specific T cell clones recognizes Arginase 1-expressing THP-1 cells

A and B - ArgLong2-specific CD4 T cell clone recognizes THP-1 cells when the Arginase 1 expression is induced by Th2 cytokine, quantified by intracellular cytokine staining. **C** - qPCR data showing that IL-13 pre-stimulation of THP-1 cells induces Arginase 1 expression.

FIGURE 10 shows *in vitro* cytokine stimulation alone is sufficient to expand T cell responses to ArgLong2 epitope

PBMCs were treated with either Arginase 1-inducing Th2 cytokine (IL-4/IL-13) or ArgLong2 peptide for 7 days before ArgLong2-specific T cells were quantified *in vitro* by IFN γ ELISPOT.

Brief Description of the Sequences

SEQ ID NOs: 1 – 9 are each an amino acid sequence of a polypeptide derived from the region corresponding to positions 161-210 of full length human Arginase 1 or murine Arginase 1.

- 5 SEQ ID NOs: 10 and 11 are the amino acid sequences of full length human Arginase 1 and murine Arginase 1, respectively.

SEQ ID NO: 12 is the amino acid sequence of the region corresponding to positions 161-210 of full length human Arginase 1.

10

SEQ ID NO: 13 is the amino acid sequence of the region corresponding to positions 161-210 of full length murine Arginase 1.

Detailed Description of the Invention

- 15 It is to be understood that different applications of the disclosed products and methods may be tailored to the specific needs in the art. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.

- 20 In addition as used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to “a polypeptide” includes “polypeptides”, and the like.

- A “polypeptide” is used herein in its broadest sense to refer to a compound of two or more subunit amino acids, amino acid analogs, or other peptidomimetics. The term “polypeptide” thus includes short peptide sequences and also longer polypeptides and
25 proteins. As used herein, the term “amino acid” refers to either natural and/or unnatural or synthetic amino acids, including both D or L optical isomers, and amino acid analogs and peptidomimetics.

- The terms “patient” and “subject” are used interchangeably and typically refer to a human.

- 30 All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.

The present inventors have previously identified a 50 amino acid region of human and murine Arginase 1 which is a “hot spot” for immunogenicity. This region corresponds to positions 161-210 of full length human Arginase 1 (SEQ ID NO: 10) or full length murine Arginase 1 (SEQ ID NO: 11). The region and peptide fragments derived from it are

5 described in WO2018065563. The present inventors have now identified that a polypeptide consisting of a specific contiguous amino acid sequence of this region is surprisingly immunogenic relative to other amino acid sequences from the same region.

By “immunogenic” herein it is meant that a polypeptide is capable of eliciting an immune response to the Arginase 1 protein, preferably when said protein is present in or on

10 cells expressing the Arginase 1 protein. In other words, the polypeptide may be described as immunogenic to Arginase 1. The polypeptide may alternatively be described as an immunogenic fragment of Arginase 1. The immune response is preferably a T cell response. The immune response may be detected in at least one individual (or in sample taken from the individual) after administration of the polypeptide to said individual (or said sample).

15 A polypeptide may be identified as immunogenic using any suitable method, including *in vitro* methods. For example, a peptide may be identified as immunogenic if it has at least one of the following characteristics:

- (i) It is capable of eliciting IFN- γ -producing cells in a PBL population of a healthy subject and/or a cancer patient as determined by an ELISPOT assay, and/or

20 (ii) It is capable of *in situ* detection in a sample of tumor tissue of CTLs that are reactive with Arginase 1; and/or

- (iii) It is capable of inducing the *in vitro* growth of specific T-cells.

Methods suitable for determining whether a polypeptide is immunogenic active are also described in the Examples section below.

25 The polypeptide of the invention may consist of:

- the amino acid sequence corresponding to positions 169-206 of full length human Arginase 1. This polypeptide may be referred to herein as ArgLong2. Its sequence is provided as SEQ ID NO: 1.

- the amino acid sequence corresponding to positions 169-206 of full length murine

30 Arginase 1. This polypeptide may be referred to herein as mArgLong2. Its sequence is provided as SEQ ID NO: 2.

- the amino acid sequence corresponding to positions 169-200 of full length human Arginase 1. This polypeptide may be referred to herein as ArgLong3. Its sequence is provided as SEQ ID NO: 3.

5 - the amino acid sequence corresponding to positions 169-200 of full length murine Arginase 1. This polypeptide may be referred to herein as mArgLong3. Its sequence is provided as SEQ ID NO: 4.

- the amino acid sequence corresponding to positions 169-210 of full length human Arginase 1. This polypeptide may be referred to herein as ArgLong. Its sequence is provided as SEQ ID NO: 5.

10 - the amino acid sequence corresponding to positions 169-210 of full length murine Arginase 1. This polypeptide may be referred to herein as mArgLong. Its sequence is provided as SEQ ID NO: 6.

The polypeptide preferably consists of the amino acid sequence of corresponding to positions 169-206 of full length human or murine Arginase 1, that is it consist of the amino acid sequence of SEQ ID NO: 1 or 2. That is, the polypeptide is preferably ArgLong2 or mArgLong2.

The polypeptide most preferably consists of the amino acid sequence of corresponding to positions 169-206 of full length human Arginase 1, that is it consists of the amino acid sequence of SEQ ID NO: 1. That is, the polypeptide is preferably ArgLong2.

20 In any polypeptide described herein, the amino acid sequence may be modified by one, two, three, four, or five (that is up to five) additions, deletions or substitutions, provided that a polypeptide having the modified sequence exhibits the same or increased immunogenicity to Arginase 1, as compared to a polypeptide having the unmodified sequence. By “the same” it is to be understood that the polypeptide of the modified sequence does not exhibit significantly reduced immunogenicity to Arginase 1 as compared to polypeptide of the unmodified sequence. Any comparison of immunogenicity between sequences is to be conducted using the same assay. Unless otherwise specified, modifications to a polypeptide sequence are preferably conservative amino acid substitutions. Conservative substitutions replace amino acids with other amino acids of similar chemical structure, similar chemical properties or similar side-chain volume. The amino acids introduced may have similar polarity, hydrophilicity, hydrophobicity, basicity, acidity, neutrality or charge to the amino acids they replace. Alternatively, the conservative substitution may introduce another amino acid that is aromatic or aliphatic in the place of a

pre-existing aromatic or aliphatic amino acid. Conservative amino acid changes are well-known in the art and may be selected in accordance with the properties of the 20 main amino acids as defined in Table A1 below. Where amino acids have similar polarity, this can be determined by reference to the hydropathy scale for amino acid side chains in Table A2.

5 **Table A1 - Chemical properties of amino acids**

Ala (A)	aliphatic, hydrophobic, neutral	Met (M)	hydrophobic, neutral
Cys (C)	polar, hydrophobic, neutral	Asn (N)	polar, hydrophilic, neutral
Asp (D)	polar, hydrophilic, charged (-)	Pro (P)	hydrophobic, neutral
Glu (E)	polar, hydrophilic, charged (-)	Gln (Q)	polar, hydrophilic, neutral
Phe (F)	aromatic, hydrophobic, neutral	Arg (R)	polar, hydrophilic, charged (+)
Gly (G)	aliphatic, neutral	Ser (S)	polar, hydrophilic, neutral
His (H)	aromatic, polar, hydrophilic, charged (+)	Thr (T)	polar, hydrophilic, neutral
Ile (I)	aliphatic, hydrophobic, neutral	Val (V)	aliphatic, hydrophobic, neutral
Lys (K)	polar, hydrophilic, charged(+)	Trp (W)	aromatic, hydrophobic, neutral
Leu (L)	aliphatic, hydrophobic, neutral	Tyr (Y)	aromatic, polar, hydrophobic

Table A2 - Hydropathy scale

	Side Chain	Hydropathy
	Ile	4.5
10	Val	4.2
	Leu	3.8
	Phe	2.8
	Cys	2.5
	Met	1.9
15	Ala	1.8
	Gly	-0.4
	Thr	-0.7
	Ser	-0.8
	Trp	-0.9
20	Tyr	-1.3
	Pro	-1.6
	His	-3.2
	Glu	-3.5
	Gln	-3.5
25	Asp	-3.5
	Asn	-3.5
	Lys	-3.9
	Arg	-4.5

30 In any polypeptide disclosed herein, any one or more of the following modifications may be made to improve physiochemical properties (e.g. stability), provided that the polypeptide exhibits the same or increased immunogenicity to Arginase 1, as compared to a polypeptide having the unmodified sequence:

- 35 a) Replacement of the C terminal amino acid with the corresponding amide (may increase resistance to carboxypeptidases);
- b) Replacement of the N terminal amino acid with the corresponding acylated amino acid (may increase resistance to aminopeptidases);

- c) Replacement of one or more amino acids with the corresponding methylated amino acids (may improve proteolytic resistance);
- d) Replacement of one or more amino acids with the corresponding amino acid in D-configuration (may improve proteolytic resistance).

5 For the modification of types (c) and (d), a preferred example is the modification of the Tyr residue in the position corresponding to position 29 of SEQ ID NO: 1 (e.g. replace with N-methyl(Tyr) or replace with D configuration Tyr). This is because the Tyr appears immediately following a Lys residue at position 28, and is thus at a potential site for proteolysis by Trypsin-like proteases (which typically cleave after Lys).

10 Any polypeptide disclosed herein may have attached at the N and/or C terminus at least one additional moiety to improve solubility, stability and/or to aid with manufacture / isolation, provided that the polypeptide exhibits the same or increased immunogenicity to Arginase 1, as compared to a polypeptide lacking the additional moiety. Suitable moieties include hydrophilic amino acids. For example, the amino acid sequences KK, KR or RR may
15 be added at the N terminus and/or C terminus. Other suitable moieties include Albumin or PEG (Polyethylene Glycol).

A polypeptide as disclosed herein may be produced by any suitable means. For example, the polypeptide may be synthesised directly using standard techniques known in the art, such as Fmoc solid phase chemistry, Boc solid phase chemistry or by solution phase
20 peptide synthesis. Alternatively, a polypeptide may be produced by transforming a cell, typically a bacterial cell, with a nucleic acid molecule or vector which encodes said polypeptide. The invention provides nucleic acid molecules and vectors which encode a polypeptide of the invention. The invention also provides a host cell comprising such a nucleic acid or vector.

25 The terms “nucleic acid molecule” and “polynucleotide” are used interchangeably herein and refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Non-limiting examples of polynucleotides include a gene, a gene fragment, messenger RNA (mRNA), cDNA, recombinant polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic
30 acid probes, and primers. A polynucleotide of the invention may be provided in isolated or substantially isolated form. By substantially isolated, it is meant that there may be substantial, but not total, isolation of the polypeptide from any surrounding medium. The polynucleotides may be mixed with carriers or diluents which will not interfere with their

intended use and still be regarded as substantially isolated. A nucleic acid sequence which “encodes” a selected polypeptide is a nucleic acid molecule which is transcribed (in the case of DNA) and translated (in the case of mRNA) into a polypeptide *in vivo* when placed under the control of appropriate regulatory sequences, for example in an expression vector. The boundaries of the coding sequence are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. For the purposes of the invention, such nucleic acid sequences can include, but are not limited to, cDNA from viral, prokaryotic or eukaryotic mRNA, genomic sequences from viral or prokaryotic DNA or RNA, and even synthetic DNA sequences. A transcription termination sequence may be located 3' to the coding sequence.

Polynucleotides can be synthesised according to methods well known in the art, as described by way of example in Sambrook *et al* (1989, Molecular Cloning - a laboratory manual; Cold Spring Harbor Press). The nucleic acid molecules of the present invention may be provided in the form of an expression cassette which includes control sequences operably linked to the inserted sequence, thus allowing for expression of the polypeptide of the invention *in vivo*. These expression cassettes, in turn, are typically provided within vectors (e.g., plasmids or recombinant viral vectors). Such an expression cassette may be administered directly to a host subject. Alternatively, a vector comprising a polynucleotide of the invention may be administered to a host subject. Preferably the polynucleotide is prepared and/or administered using a genetic vector. A suitable vector may be any vector which is capable of carrying a sufficient amount of genetic information, and allowing expression of a polypeptide of the invention.

The present invention thus includes expression vectors that comprise such polynucleotide sequences. Such expression vectors are routinely constructed in the art of molecular biology and may for example involve the use of plasmid DNA and appropriate initiators, promoters, enhancers and other elements, such as for example polyadenylation signals which may be necessary, and which are positioned in the correct orientation, in order to allow for expression of a peptide of the invention. Other suitable vectors would be apparent to persons skilled in the art. By way of further example in this regard we refer to Sambrook *et al*.

The invention also includes cells that have been modified to express a polypeptide of the invention. Such cells typically include prokaryotic cells such as bacterial cells, for

example *E. coli*. Such cells may be cultured using routine methods to produce a polypeptide of the invention.

The polypeptide of the invention may be in a substantially isolated form. It may be mixed with carriers, preservatives, or diluents (discussed below) which will not interfere with the intended use, and/or with an adjuvant (also discussed below) and still be regarded as substantially isolated. It may also be in a substantially purified form, in which case it will generally comprise at least 90%, e.g. at least 95%, 98% or 99%, of the protein in the preparation.

Compositions comprising polypeptides or polynucleotides

In another aspect, the present invention provides a composition comprising a polypeptide of the invention. The present invention also provides a composition comprising a polynucleotide encoding a polypeptide of the invention. For example, the invention provides a composition comprising one or more polypeptides of the invention, and at least one pharmaceutically acceptable carrier, preservative or excipient. Alternatively, the invention provides a composition comprising one or more polynucleotides encoding a polypeptide of the invention, and at least one pharmaceutically acceptable carrier, preservative or excipient. The carrier, preservative and excipient must be 'acceptable' in the sense of being compatible with the other ingredients of the composition and not deleterious to a subject to which the composition is administered. Typically, all components and the final composition are sterile and pyrogen free. The composition may be a pharmaceutical composition. The composition may preferably comprise an adjuvant.

Adjuvants are any substance whose admixture into the composition increases or otherwise modifies the immune response elicited by the composition. Adjuvants, broadly defined, are substances which promote immune responses. Adjuvants may also preferably have a depot effect, in that they also result in a slow and sustained release of an active agent from the administration site. A general discussion of adjuvants is provided in Goding, *Monoclonal Antibodies: Principles & Practice* (2nd edition, 1986) at pages 61-63.

Adjuvants may be selected from the group consisting of: $\text{AlK}(\text{SO}_4)_2$, $\text{AlNa}(\text{SO}_4)_2$, $\text{AlNH}_4(\text{SO}_4)$, silica, alum, $\text{Al}(\text{OH})_3$, $\text{Ca}_3(\text{PO}_4)_2$, kaolin, carbon, aluminum hydroxide, muramyl dipeptides, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-DMP), N-acetyl-nornuramyl-L-alanyl-D-isoglutamine (CGP 11687, also referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1'2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, also referred to as MTP-PE), RIBI

(MPL+TDM+CWS) in a 2% squalene/Tween-80.RTM. emulsion, lipopolysaccharides and its various derivatives, including lipid A, Freund's Complete Adjuvant (FCA), Freund's Incomplete Adjuvants, Merck Adjuvant 65, polynucleotides (for example, poly IC and poly AU acids), wax D from Mycobacterium, tuberculosis, substances found in Corynebacterium parvum, Bordetella pertussis, and members of the genus Brucella, Titermax, ISCOMS, Quil A, ALUN (see US 58767 and 5,554,372), Lipid A derivatives, cholera toxin derivatives, HSP derivatives, LPS derivatives, synthetic peptide matrixes or GMDP, Interleukin 1, Interleukin 2, Montanide ISA-51 and QS-21. Various saponin extracts have also been suggested to be useful as adjuvants in immunogenic compositions. Granulocyte-macrophage colony stimulating factor (GM-CSF) may also be used as an adjuvant.

Preferred adjuvants to be used with the invention include oil/surfactant based adjuvants such as Montanide adjuvants (available from Seppic, Belgium), preferably Montanide ISA-51. Other preferred adjuvants are bacterial DNA based adjuvants, such as adjuvants including CpG oligonucleotide sequences. Yet other preferred adjuvants are viral dsRNA based adjuvants, such as poly I:C. GM-CSF and Imidazochinilines are also examples of preferred adjuvants.

The adjuvant is most preferably a Montanide ISA adjuvant. The Montanide ISA adjuvant is preferably Montanide ISA 51 or Montanide ISA 720.

In Goding, Monoclonal Antibodies: Principles & Practice (2nd edition, 1986) at pages 61-63 it is also noted that, when an antigen of interest is of low molecular weight, or is poorly immunogenic, coupling to an immunogenic carrier is recommended. A polypeptide of the invention may therefore be coupled to a carrier. A carrier may be present independently of an adjuvant. The function of a carrier can be, for example, to increase the molecular weight of a polypeptide fragment in order to increase activity or immunogenicity, to confer stability, to increase the biological activity, or to increase serum half-life. Furthermore, a carrier may aid in presenting the polypeptide or fragment thereof to T-cells. Thus, in the composition, the polypeptide may be associated with a carrier such as those set out below.

The carrier may be any suitable carrier known to a person skilled in the art, for example a protein or an antigen presenting cell, such as a dendritic cell (DC). Carrier proteins include keyhole limpet hemocyanin, serum proteins such as transferrin, bovine serum albumin, human serum albumin, thyroglobulin or ovalbumin, immunoglobulins, or hormones, such as insulin or palmitic acid. Alternatively the carrier protein may be tetanus toxoid or

diphtheria toxoid. Alternatively, the carrier may be a dextran such as sepharose. The carrier must be physiologically acceptable to humans and safe.

If the composition comprises an excipient, it must be 'pharmaceutically acceptable' in the sense of being compatible with the other ingredients of the composition and not deleterious to the recipient thereof. Auxiliary substances, such as wetting or emulsifying agents, pH buffering substances and the like, may be present in the excipient. These excipients and auxiliary substances are generally pharmaceutical agents that do not induce an immune response in the individual receiving the composition, and which may be administered without undue toxicity. Pharmaceutically acceptable excipients include, but are not limited to, liquids such as water, saline, polyethyleneglycol, hyaluronic acid, glycerol and ethanol. Pharmaceutically acceptable salts can also be included therein, for example, mineral acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, and the like; and the salts of organic acids such as acetates, propionates, malonates, benzoates, and the like. A thorough discussion of pharmaceutically acceptable excipients, vehicles and auxiliary substances is available in Remington's Pharmaceutical Sciences (Mack Pub. Co., N.J. 1991).

Formulation of a suitable composition can be carried out using standard pharmaceutical formulation chemistries and methodologies all of which are readily available to the reasonably skilled artisan. Such compositions may be prepared, packaged, or sold in a form suitable for bolus administration or for continuous administration. Injectable compositions may be prepared, packaged, or sold in unit dosage form, such as in ampoules or in multi-dose containers optionally containing a preservative. Compositions include, but are not limited to, suspensions, solutions, emulsions in oily or aqueous vehicles, pastes, and implantable sustained-release or biodegradable formulations. In one embodiment of a composition, the active ingredient is provided in dry (for e.g., a powder or granules) form for reconstitution with a suitable vehicle (e. g., sterile pyrogen-free water) prior to administration of the reconstituted composition. The composition may be prepared, packaged, or sold in the form of a sterile injectable aqueous or oily suspension or solution. This suspension or solution may be formulated according to the known art, and may comprise, in addition to the active ingredient, additional ingredients such as the adjuvants, excipients and auxiliary substances described herein. Such sterile injectable formulations may be prepared using a non-toxic parenterally-acceptable diluent or solvent, such as water or 1,3-butane diol, for example. Other acceptable diluents and solvents include, but are not limited to, Ringer's solution, isotonic sodium chloride solution, and fixed oils such as synthetic mono- or di-

glycerides. Other compositions which are useful include those which comprise the active ingredient in microcrystalline form, in a liposomal preparation, or as a component of a biodegradable polymer systems. Compositions for sustained release or implantation may comprise pharmaceutically acceptable polymeric or hydrophobic materials such as an emulsion, an ion exchange resin, a sparingly soluble polymer, or a sparingly soluble salt. Alternatively, the active ingredients of the composition may be encapsulated, adsorbed to, or associated with, particulate carriers. Suitable particulate carriers include those derived from polymethyl methacrylate polymers, as well as PLG microparticles derived from poly(lactides) and poly(lactide-co-glycolides). See, e.g., Jeffery et al. (1993) Pharm. Res. 10:362-368. Other particulate systems and polymers can also be used, for example, polymers such as polylysine, polyarginine, polyornithine, spermine, spermidine, as well as conjugates of these molecules.

Methods of use

The polypeptide, polynucleotide or composition of the invention may be used in a method of treating or preventing a disease or condition in a subject. The polypeptide, polynucleotide or composition of the invention may be used in the manufacture of a medicament for use in a method of treating or preventing a disease or condition in a subject. The method comprises administering to the said subject the said polypeptide, the said polynucleotide or the said composition. Administration may be of a therapeutically or prophylactically effective quantity of the said polypeptide, the said polynucleotide or the said composition, to a subject in need thereof.

The disease or condition may be characterized at least in part by inappropriate or excessive immune suppressive function of Arginase 1. The disease or condition may be a cancer, preferably a cancer which expresses Arginase 1 and/or which is associated with inappropriate or excessive immune suppressive function of Arginase 1. The cancer may be breast, lung, colon or prostate cancer, or may be a leukemia, preferably acute myeloid leukemia (AML), or may be a melanoma.

The method may comprise simultaneous or sequential administration with an additional cancer therapy. The additional cancer therapy may be selected from a cytokine therapy, a T-cell therapy, an NK therapy, an immune system checkpoint inhibitor, chemotherapy, radiotherapy, immunostimulating substances, gene therapy, or an antibody.

- The antibody may be Abagovomab, Abciximab, Actoxumab, Adalimumab, Adecatumumab, Afelimomab, Afutuzumab, Alacizumab pegol, ALD518, Alemtuzumab, Alirocumab, Altumomab pentetate, Amatuximab, Anatumomab mafenatox, Anrukinzumab, Apolizumab, Arcitumomab, Aselizumab, Atinumab, Atlizumab (= tocilizumab),
- 5 Atorolimomab, Bapineuzumab, Basiliximab, Bavituximab, Bectumomab, Belimumab, Benralizumab, Bertilimumab, Besilesomab, Bevacizumab, Bezlotoxumab, Biciromab, Bimagrumab, Bivatuzumab mertansine, Blinatumomab, Blosozumab, Brentuximab vedotin, Briakinumab, Brodalumab, Canakinumab, Cantuzumab mertansine, Cantuzumab ravtansine, Caplacizumab, Capromab pendetide, Carlumab, Catumaxomab, CC49, Cedelizumab,
- 10 Certolizumab pegol, Cetuximab, Ch.14.18, Citatuzumab bogatox, Cixutumumab, Clazakizumab, Clenoliximab, Clivatuzumab tetraxetan, Conatumumab, Concizumab, Crenezumab, CR6261, Dacetuzumab, Daclizumab, Dalotuzumab, Daratumumab, Demcizumab, Denosumab, Detumomab, Dorlimomab aritox, Drozitumab, Duligotumab, Dupilumab, Dusigitumab, Echromeximab, Eculizumab, Edobacomab, Edrecolomab,
- 15 Efalizumab, Efungumab, Elotuzumab, Elsilimomab, Enavatuzumab, Enlimomab pegol, Enokizumab, Enoticumab, Ensituximab, Eptumomab cituxetan, Epratuzumab, Erlizumab, Ertumaxomab, Etaracizumab, Etrolizumab, Evolocumab, Exbivirumab, Fanolesomab, Faralimomab, Farletuzumab, Fasinumab, FBT A05, Felvizumab, Fezakinumab, Ficlaturumab, Figitumumab, Flanvotumab, Fontolizumab, Foralumab, Foravirumab, Fresolimumab,
- 20 Fulranumab, Futuximab, Galiximab, Ganitumab, Gantenerumab, Gavilimomab, Gemtuzumab, ozogamicin, Gevokizumab, Girentuximab, Glembatumumab vedotin, Golimumab, Gomiliximab, GS6624, Ibalizumab, Ibritumomab tiuxetan, Icrucumab, Igovomab, Imciromab, Imgatuzumab, Inclacumab, Indatuximab ravtansine, Infliximab, Intetumumab, Inolimomab, Inotuzumab ozogamicin, Ipilimumab, Iratumumab, Itolizumab, Ixekizumab, Keliximab,
- 25 Labetuzumab, Lampalizumab, Lebrikizumab, Lemalesomab, Lerdelimomab, Lexatumumab, Libivirumab, Ligelizumab, Lintuzumab, Lirilumab, Lodelcizumab, Lorvotuzumab, mertansine, Lucatumumab, Lumiliximab, Mapatumumab, Maslimomab, Mavrilimumab, Matuzumab, Mepolizumab, Metelimomab, Milatuzumab, Minretumomab, Mitumomab, Mogamulizumab, Morolimumab, Motavizumab, Moxetumomab pasudotox, Muromonab-
- 30 CD3, Nacolomab tafenatox, Namilumab, Naptumomab estafenatox, Narnatumab, Natalizumab, Nebacumab, Necitumumab, Nerelimomab, Nesvacumab, Nimotuzumab, Nivolumab, Nofetumomab merpentan, Obinutuzumab, Ocaratuzumab, Ocrelizumab, Odulimumab, Ofatumumab, Olaratumab, Olokizumab, Omalizumab, Onartuzumab,

Oportuzumab monatox, Oregovomab, Orticumab, Otelixizumab, Oxelumab, Ozanezumab, Ozoralizumab, Pagibaximab, Palivizumab, Panitumumab, Panobacumab, Parsatuzumab, Pascolizumab, Pateclizumab, Patritumab, Pemtumomab, Perakizumab, Pertuzumab, Pexelizumab, Pidilizumab, Pinatuzumab vedotin, Pintumomab, Placulumab, Polatuzumab vedotin, Ponezumab, Priliximab, Pritoxaximab, Pritumumab, PRO 140, Quilizumab, Racotumomab, Radretumab, Rafivirumab, Ramucirumab, Ranibizumab, Raxibacumab, Regavirumab, Reslizumab, Rilotumumab, Rituximab, Robatumumab, Roledumab, Romosozumab, Rontalizumab, Rovelizumab, Ruplizumab, Samalizumab, Sarilumab, Satumomab pendetide, Secukinumab, Seribantumab, Setoxaximab, Sevirumab, Sibrotuzumab, Sifalimumab, Siltuximab, Simtuzumab, Siplizumab, Sirukumab, Solanezumab, Solitomab, Sonepcizumab, Sontuzumab, Stamulumab, Sulesomab, Suvizumab, Tabalumab, Tacatuzumab tetraxetan, Tadocizumab, Talizumab, Tanezumab, Taplitumomab paptox, Tefibazumab, Telimomab aritox, Tenatumomab, Teneliximab, Teplizumab, Teprotumumab, TGN1412, Ticilimumab (= tremelimumab), Tildrakizumab, Tigatuzumab, TNX-650, Tocilizumab (= atlizumab), Toralizumab, Tositumomab, Tralokinumab, Trastuzumab, TRBS07, Tregalizumab, Tremelimumab Tucotuzumab celmoleukin, Tuvirumab, Ublituximab, Urelumab, Urtoxazumab, Ustekinumab, Vapaliximab, Vatelizumab, Vedolizumab, Veltuzumab, Vepalimomab Vesencumab, Visilizumab, Volociximab, Vorsetuzumab mafodotin, Votumumab, Zalutumumab, Zanolimumab, Zatuximab, Ziralimumab or Zolimomab aritox.

Preferred antibodies include Natalizumab, Vedolizumab, Belimumab, Atacicept, Alefacept, Otelixizumab, Teplizumab, Rituximab, Ofatumumab, Ocrelizumab, Epratuzumab, Alemtuzumab, Abatacept, Eculizumab, Omalizumab, Canakinumab, Meplizumab, Reslizumab, Tocilizumab, Ustekinumab, Briakinumab, Etanercept, Infliximab, Adalimumab, Certolizumab pegol, Golimumab, Trastuzumab, Gemtuzumab, Ozogamicin, Ibritumomab, Tiuxetan, Tositumomab, Cetuximab, Bevacizumab, Panitumumab, Denosumab, Ipilimumab, Brentuximab and Vedotin.

Particularly preferred antibodies that may be used in the method of the invention include: daratumumab, nivolumab, pembrolizumab, avelumab, rituximab, trastuzumab, pertuzumab, alemtuzumab, cetuximab, panitumumab, tositumomab and ofatumumab. Daratumumab is especially preferred.

The additional cancer therapy may be selected from the group consisting of Actimide, Azacitidine, Azathioprine, Bleomycin, Carboplatin, Capecitabine, Cisplatin, Chlorambucil,

Cyclophosphamide, Cytarabine, Dauno-rubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluor-ouracil, Gemcitabine, Hydroxyurea, Idarubicin, Irinotecan, Lenalidomide, Leucovorin, Mechlorethamine, Melphalan, Mercaptopurine, Methotrexate, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Revlimid, Temozolomide, Teniposide, Thioguanine, Valrubicin, Vinblastine, Vincristine, Vindesine and Vinorelbine.

The polypeptide or composition of the invention may also be used in a method of stimulating Arginase 1-specific T cells, such as CD4 and CD8 T-cells, comprising contacting cells with the said polypeptide or composition. The method may be conducted ex vivo. The cells may be present in a sample taken from a healthy subject or from a cancer patient, such as in a tumour sample.

The present invention is further illustrated by the following examples that, however, are not to be construed as limiting the scope of protection. The features disclosed in the foregoing description and in the following examples may, both separately and in any combination thereof, be material for realizing the invention in diverse forms thereof.

Example 1

MATERIALS AND METHODS

Patient material

PBMCs from healthy donors were isolated using density gradient separation over Lymphoprep™ (STEMCELL Technologies) and cryopreserved at -150°C in FBS supplemented with 10% DMSO. PBMCs from cancer patients were isolated from blood sample a minimum of four weeks after the termination of any anti-cancer therapy. The protocol was approved by the Scientific Ethics Committee for The Capital Region of Denmark and conducted in accordance with the provisions of the Declaration of Helsinki. Written informed consent from the patients was obtained before study entry.

Peptides

Peptides were synthesized by standard methods and provided dissolved in DMSO to obtain a stock concentration of 10mM. The sequences of the peptides used in these experiments are shown in full below in alignment with each other, and are also set out in the section entitled “Sequences”). Peptides are described by SEQ ID NO, by name, or by reference to the start

and end positions of each peptide sequence within the full length sequence of Arginase 1. Each may be used interchangeably. For example, the peptide of SEQ ID NO: 1 may alternatively be referred to by the name ArgLong2, or may alternatively be referred to as Arg169-206 (given a start position of 169 and end position of 206). The intended reference in each case will be clear from the context.

Longer peptide sequences:

ArgLong: ISAKDIVYIGLRDVPGEHYILKTLGIKYFSMTEVDRLGIGK

ArgLong2: ISAKDIVYIGLRDVPGEHYILKTLGIKYFSMTEVDRL

10 ArgLong3: ISAKDIVYIGLRDVPGEHYILKTLGIKYFSM

20-mer peptides:

Arg₁₇₁₋₁₉₀: AKDIVYIGLRDVPGEHYIL

Arg₁₈₁₋₂₀₀: DVDPGEHYILKTLGIKYFSM

Arg₁₉₁₋₂₁₀: KTLGIKYFSMTEVDRLGIGK

15

ELISPOT assay

For *in vitro* ELISPOT, PBMCs from cancer patients and healthy donors were pulsed with 20 μ M of Arginase 1-derived peptides and 120 U/ml IL-2 in 24-well plates for 7 days before being used in an ELISPOT assay. The cells were placed in 96-well nitrocellulose ELISPOT plates (MultiScreen MAIP N45; Millipore) pre-coated with IFN γ capture antibody (Mabtech). Arginase peptides added to a final concentration of 5 μ M and plates incubated at 37°C for 14-16 hours. After the incubation the cells were washed off and secondary biotinylated Ab (Mabtech, cat. 3420-6-1000) was added for 2 hours at room temperature. Unbound secondary antibody was washed off and streptavidin conjugated alkaline phosphatase (AP) (Mabtech, cat. 3310-10) was added for 1 hour at room temperature. Unbound conjugated enzyme was washed off and the assay was developed by adding BCIP/NBT substrate (Mabtech, cat. 3650-10). Developed ELISPOT plates were analyzed on CTL ImmunoSpot S6 Ultimate-V analyzer using Immunospot software v5.1. Responses were reported as the difference between average numbers of spots in wells stimulated with Arginase 1 and wells without added peptide.

To check for IL-4 induced Arg1 responses, PBMCs were stimulated with IL-4 (100 or 50U/ml) and/or IL-2 (120 or 60U/ml) for a week before being set up in the ELISPOT assay as described above.

Intracellular staining

Intracellular staining of cell cultures was performed after PBMCs were stimulated with arginase-derived peptides for 5 hours in the presence of BD GolgiPlug™ (added after the first hour of peptide stimulation). Stimulated cells were stained with fluorescently labeled antibodies for surface markers (CD3, CD4, CD8) and thereafter permeabilized by using Fixation/Permeabilization and Permeabilization Buffer (eBioscience, cat. 00-5123-43), according to manufacturer's instructions. Permeabilized cells were then stained with fluorochrome-labeled antibodies for IFN γ and TNF α . Flow cytometry analysis was performed on a FACSCanto™ II (BD Biosciences). Antibodies used: IFN γ -APC (cat.341117), TNF α -455 BV421 (cat.562783), CD4-FITC (cat.347413), CD8-PerCP (cat.345774), CD3-APC-H7 (cat. 560275) (all from BD Biosciences), dead cells stain-FVS510 (564406, BD Biosciences) according to manufacturer's instructions.

Memory T cell sorting

CD4+ and CD8+ memory T cells were sorted from freshly thawed healthy donor or cancer patient PBMC samples using magnetic bead sorting kits: Memory CD4+ T Cell Isolation Kit, human (cat. 130-091-893, Miltenyi Biotec) and CD8+ Memory T Cell Isolation Kit, human (cat. 130-094-412, Miltenyi Biotec). The purity of isolated cells was assessed by staining for CD4-FITC, CD8-PerCP, CD45RO-PE (all from BD Biosciences), dead cells were stained using LIVE/DEAD™ Fixable Near-IR Dead Cell Stain Kit (Invitrogen™, ThermoFisher Scientific).

RESULTS

25

Arginase 1 peptide length determines the efficiency of T cell stimulation

Based on the previously identified 50-amino acid long Arg1 hotspot region at positions 161-210 of Arginase 1, three different peptides that covered the major part this region were chosen, which also excluded the cysteine at position 168 of Arginase 1 (expected to improve manufacturability, solubility and stability). The three peptides were: 42-mer ArgLong (positions 169-210), 38-mer ArgLong2 (positions 169-206) and 32-mer ArgLong3 (positions 169-200).

To test whether these peptides could be used to identify Arginase 1 responses, PBMCs from 6 healthy donors were screened for responses in IFN γ ELISPOT. PBMCs were stimulated with ArgLong2 peptide and low dose IL-2 for 1 week prior to ELISPOT. Despite the similarities in sequence, the ArgLong2 peptide appeared to be superior at stimulating T cell responses in IFN γ ELISPOT. As shown in Figure 1, high responses against ArgLong2 peptide were seen in 4 out of 6 donors, while low or no responses were present against ArgLong and ArgLong3 peptides.

ArgLong2 is only 4 amino acids shorter than ArgLong and 6 amino acids longer than ArgLong3. This suggests that the peptide length and sequence may play a crucial role in ensuring optimal processing and presentation of arginase peptides. As a consequence, it may have an effect on the ability of such peptides to activate Arg1 specific T cells.

To determine whether the ArgLong2 peptide is comparable to previously described individual 20-mer peptides covering the same sequence (see WO2018065563 Examples 1, 2 and 3), PBMCs from 19 healthy donors and 16 cancer patients (8 melanoma, 6 multiple myeloma, 1 breast cancer and 1 renal cell carcinoma) were screened for responses against three 20-mer peptides and the 38-mer ArgLong2. In both cancer patients and healthy donors, ArgLong2 produced the most responses compared to all three 20-mer peptides (see Figure 2). Strong responses against ArgLong2 were seen in 14 out of 19 healthy donors and 8 out of 16 cancer patients. Responses were also seen against 20-mer peptides, although these were fewer and lower. In summary: Arg₁₇₁₋₁₉₀ showed responses in 3 healthy donors and 3 cancer patients, Arg₁₈₁₋₂₀₀ showed responses in 4 healthy donors and 6 cancer patients, Arg₁₉₁₋₂₁₀ showed responses in 7 healthy donors and 3 cancer patients.

CD4+ and CD8+ responses against Arginase 1

Previously described T cell responses against 20-mer Arg1 peptides have shown predominantly CD4+ T cell responses in cancer patients and healthy donors (see WO2018065563 Example 2). Since the ArgLong2 peptide appeared to be more efficiently processed and subsequently recognized by T cells, the type of T cell responses to ArgLong2 was investigated by intracellular staining.

PBMCs from two healthy donors (HD384, HD400) and one breast cancer patient (BD30) that had previously shown strong responses against ArgLong2 in ELISPOT were tested by intracellular staining one week after *in vitro* stimulation with ArgLong2 and low dose IL-2. Remarkably, both CD4+ and CD8+ T cell responses against ArgLong2 peptide

were identified in the cancer patient and healthy donors. Both CD4+ responses (left panel of Figure 3A) and CD8+ responses (right panel of Figure 3A) were detected in one healthy donor and in the breast cancer patient PBMCs. The other healthy donor showed only CD8+ T cell response.

5 Interestingly, detectable CD4+ and CD8+ responses against ArgLong2 were also seen in intracellular staining of PBMCs without prior peptide stimulation. PBMCs from two cancer patients (one malignant melanoma (MM27) and one breast cancer (BC30)) were thawed and directly tested for responses against ArgLong2 peptide in *ex vivo* intracellular staining. We were able to detect *ex vivo* CD4+ responses in PBMCs from both cancer
10 patients (Figure 3B, left) and *ex vivo* CD8+ responses in the breast cancer patient PBMCs (Figure 3B, right).

Memory CD4+ and CD8+ responses against Arginase 1

Strong responses seen against ArgLong2 indicated that the frequencies of Arg1-
15 specific T cells could be more commonly detectable in PBMCs without any prior peptide stimulation. PBMCs from 4 healthy donors and 2 cancer patients (1 breast cancer and 1 malignant melanoma) that had shown strong responses in *in vitro* ELISPOT were directly tested for responses to ArgLong2 peptide in *ex vivo* IFN γ ELISPOT. We found significant spontaneous responses in all 6 donors (See Figure 4A).

20 Presence of strong spontaneous *ex vivo* responses against ArgLong2 peptide in PBMCs of healthy donors and cancer patient suggested that Arginase 1-specific cells are a natural part of the immune system. To test that CD4+ and CD8+ memory T cells were sorted from PBMCs of cancer patients and healthy donors that had shown a strong spontaneous immune response *ex vivo*. CD4+ or CD8+ memory T cells were sorted from PBMCs of 4
25 healthy donors and 2 cancer patients using magnetic bead sorting and set up in *ex vivo* IFN γ ELISPOT. The purity of memory T cell isolation was confirmed by flow cytometric analysis for CD4+CD45RO+ and CD8+CD45RO+ T cells and was determined to be >95%. We found CD4+ memory responses against ArgLong2 peptide in 2 cancer patients and 3 healthy donors (see Figure 4B). Clear CD8+ memory responses could be detected in 2 healthy donors (see
30 Figure 4C).

IL-4 upregulated Arginase 1 expression increases T cell responses against ArgLong2

Since Arg1-specific CD4+ and CD8+ memory T cells are present in both cancer patients and healthy donors, it was tested whether these T cells could be involved in immune regulation in response to upregulated Arg1 expression. Arg1 has been previously described to be upregulated in myeloid cells in response to IL-4.

5 First, PBMCs from a single melanoma patient that had previously been shown to have a strong spontaneous against ArgLong2 peptide response *ex vivo* were tested. The PBMCs were thawed and stimulated with IL-4, (50U/ml or 100U/ml), IL-2 (120U/ml) or a combination of IL-4 and IL-2 (50U/ml and 60U/ml respectively) for one week before being tested in IFN γ ELISPOT for responses against ArgLong2. Non-stimulated cells were used as
10 control. Strong significant responses were seen in all IL-4 stimulated groups: highest responses were seen against IL-4 stimulated groups as compared to no stimulation or stimulation with IL-2 alone, suggesting that Arg1 specific T cells are activated in response to upregulated Arg1 expression. See Figure 5A.

Next, PBMCs from 2 cancer patients (BC30 (breast cancer), MM27 (malignant
15 melanoma)) and 6 healthy donors that had previously shown strong spontaneous *ex vivo* responses against ArgLong2 were stimulated with either low dose IL-2 (120U/ml) or IL-4 (100U/ml) for 7 days. Non-stimulated cells were used as control. After 7 days in culture, PBMCs were tested for reactivity against ArgLong2 in IFN γ ELISPOT. 6 out of 8 cultures showed increase responses against ArgLong2 in IL-4 stimulated cultures compared to
20 unstimulated and IL-2 stimulated controls, further confirming the possible common mechanism of Arg1- specific T cell activation *in vivo*. See Figure 5B.

DISCUSSION

The existence of Arg1 specific T cells has been previously described. Such T cells
25 may be called “anti-Tregs” due to their role in targeting immune regulatory proteins. Anti-Treg responses against other immune regulatory proteins, such as PD-L1 and IDO have also been described. The above experiments demonstrate that Arginase 1 specific anti-Tregs are not only spontaneously present in cancer patients and healthy donors but also exist as part of memory T-cell repertoire, as responses against ArgLong2 peptide were seen in isolated CD4+
30 and CD8+ memory T cell populations.

In order to keep the immune balance, regulatory immune cells, e.g., Tregs, different dendritic cell subtypes, myeloid derived suppressor cells, and M2 macrophages suppress or terminate immune responses. This regulatory arm secures unresponsiveness or tolerance to

self-antigens. Regulatory immune cells suppress immunity through a number of different cellular and extracellular factors. In contrast, specific anti-Tregs recognizing HLA-restricted derived epitopes which are generated from intracellular degraded antigens are able directly to eliminate regulatory immune cells. In addition, anti-Tregs can boost local immune activation by the secretion of effector cytokines.

T_H2 -driven lung inflammation increases Arginase 1 expression in myeloid cells. Especially, IL-4, the prototypical inducer of the macrophage M2 phenotype, induced Arginase 1 upregulation. It has been shown here that Arginase 1-specific T cells are activated in response to the T_H2 cytokine IL-4. Hence, this suggests that Arginase 1 specific T_H1 cells infiltrate IL-4 increased environments and drive the immune response back into the T_H1 pathway, which could be an important role of Arginase 1 specific anti-Tregs in controlling the immune inhibition and promoting inflammation. However, Arginase 1-specific anti-Tregs themselves are hampered by the suppressive effects of Arginase 1 expressing regulatory immune cells. Thus, in immune regulatory networks, Arginase 1 specific anti-Tregs suppress the function of Arginase 1+ regulatory immune cells and vice versa. Hence, under normal physiological conditions equilibrium between immune activation and suppression may be necessary to maintain immune homeostasis.

The findings of memory T cells specific for Arginase 1 in healthy individuals, which are expanded in response to IL-4, is in line with previously findings regarding IDO and PD-L1 specific anti-Tregs. Circulating IDO- or PD-L1 specific anti-Tregs have been identified as present in healthy donors, although detection was not as frequent as detection in patients with cancer. Additionally, it has been found that the pro-inflammatory cytokines IL-2 and IFN- γ , which are known to induce IDO and PD-L1, expand populations of IDO- or PD-L1 specific T cells among human PBMCs without additional stimulation.

Expression of Arginase 1 in the tumor microenvironment by immune suppressive myeloid cells inhibits anti-tumor T cell responses through L-arginine depletion. In an Arginase 1 positive environment T cells cannot proliferate, and a promising therapeutic strategy is thus to reconstitute the adaptive immune responses by the activation of pro-inflammatory Arginase 1-specific T cells. Activation of Arginase 1-specific anti-Tregs by peptide vaccination offers a novel approach at targeting of a specific immune inhibitory mechanism in cancer.

Developing new immune-therapeutic approaches in cancer treatment is likely to be most efficient and versatile when common suppressive mechanisms are targeted. As shown in

these experiments. Arginase 1-specific anti-Tregs exist as a natural part of the immune system and can be readily employed to tilt the balance away from immune suppression in cancer.

The peptide ArgLong2, which covers the majority of the previously described Arginase 1 hotspot region, has been shown to be particularly efficient at stimulating arginase-specific CD4+ and CD8+ T cell responses as compared to similar peptides of different lengths. ArgLong2 therefore has particularly high likelihood for success in a vaccination setting, given its potential to stimulate Arginase 1-specific anti-Tregs which may exert both effector and helper functions in the tumor microenvironment.

Example 2 – Design of additional peptides

In order to design peptides suitable for use in vaccination experiments in mice, and which may also be functional in humans, the sequence of murine Arginase 1 (SEQ ID NO: 11) was compared to the human Arginase 1 sequence of SEQ ID NO: 10. The level of similarity is particularly high in the hotspot region of human Arginase 1 corresponding to positions 161-210 of SEQ ID NO: 1. An alignment of this region and the corresponding region in murine Arginase 1 is also shown below:

```
hArg1: GFSWVTPCISAKDIVYIGLRDVPGEHYILKTLGIKYFSMTEVDRLGIGK (SEQ ID NO: 12)
mArg1: GFSWVTPCISAKDIVYIGLRDVPGEHYILKTLGIKYFSMTEVDKLGIGK (SEQ ID NO: 13)
```

Only 2 residues of the 50 differ, shown as bold and underlined. A leucine in the human sequence is substituted for the highly similar aliphatic amino acid isoleucine in the mouse, and an arginine in the human sequence is substituted for the similarly basic lysine in the mouse. Both changes are conservative. Accordingly the hotspot region is highly conserved between humans and mice. Polypeptides of the invention therefore include polypeptides which consist of a particular human sequence from the hotspot region, but in which the substitutions for the corresponding mouse sequence are made. For example, SEQ ID NO: 2 corresponds to SEQ ID NO:1 but with both the above-mentioned leucine-isoleucine and arginine-lysine substitutions. The polypeptide consisting of SEQ ID NO: 2 may be referred to herein as mArgLong2. Similarly, SEQ ID NO: 4 corresponds to SEQ ID NO: 3 but with the above-mentioned leucine-isoleucine substitution. The polypeptide consisting of SEQ ID NO: 2 may be referred to herein as mArgLong3. Similarly, SEQ ID NO: 6 corresponds to SEQ ID NO: 5 but with both the above-mentioned leucine-isoleucine and arginine-lysine substitutions. The polypeptide consisting of SEQ ID NO: 6 may be referred to herein as

mArgLong. The murine peptides are expected to have similar potential as vaccines to their human counterparts.

Example 3 - *in vivo* experiments with human ArgLong2 peptide in murine tumor

models

In order to demonstrate the therapeutic potential of vaccination using the ArgLong2 peptide, mouse models were developed. Since the corresponding ArgLong2 sequence in mice differ by only two amino acids, the human ArgLong2 sequence was employed in the subsequent experiments. A comparison of the human and mouse ArgLong2 sequences is shown below:

Human ArgLong2 (SEQ ID NO: 1) - ISAKDIVYIGLRDVPGEHYI**L**KTLGIKYFSMTEVD**R**L

Mouse ArgLong2 (SEQ ID NO: 2) - ISAKDIVYIGLRDVPGEHYI**I**KTLGIKYFSMTEVD**K**L

MATERIALS AND METHODS

Peptide vaccination of C57BL/6 mice

Animals were vaccinated subcutaneously with 100 µg peptide in DMSO/H₂O in a 1:1 emulsion with incomplete Montanide ISA 51 VG. Montanide ISA 51 VG + DMSO/H₂O served as a control vaccine. For subsequent analysis of the immune response to the ArgLong2 peptide, mice were sacrificed on day 7 and spleen and draining lymph nodes (dLNs) were harvested for ELISPOT setup.

ELISPOT analysis of peptide-specific response

Murine immune cells were subjected to ELISPOT analysis. Single cell suspension was prepared from spleen or dLNs by passage through a cell strainer. After lysis of red blood cells, $0.6-0.8 \times 10^6$ cells/well were seeded into ELISPOT plates coated with anti-IFN γ antibody. Peptide of interest was added to designated wells and cells were incubated overnight with peptide. The next day, cells were removed, plates washed and incubated with biotinylated detection antibody. Finally, after addition of Streptavidin-ALP and substrate visible spots appear. Each spot corresponds to an individual IFN γ producing cell. Plates were analysed in an Immunospot analyser and plotted.

Tumour vaccination of female C57BL/6 mice, age 15-16/17-20 weeks, 15 animals per group

Each animal was inoculated subcutaneously into the right flank with 0.5×10^6 syngeneic tumour cells in 100 μ l media. Both the syngeneic B16 F10 melanoma cells line and the syngeneic MC38 colon adenocarcinoma cell line were used. Vaccinations were initiated on day 0 and repeated once a week (day 7 and day 14). Peptide and control vaccinations were performed as described above.

Tumour growth was monitored and tumours were measured approximately every second day. Tumour volume was calculated at $V[\text{mm}^3] = L \times W^2/2$ (where L is the longest diameter and W perpendicular to L). Maximum tumor size before mice were euthanized was 864 mm^3 (L=12 mm, W=12 mm).

RESULTS

ArgLong2 was found to be strongly immunogenic in C57BL/6 mice, shown by high frequency of vaccine-specific T cell responses detected after just one vaccination (**Figure 6**).

In the tumour studies, vaccinations with ArgLong2 significantly delay tumour growth as compared to control vaccination. The delay in tumor growth was observed in both the MC38 model for colon adenocarcinoma (**Figure 7**) and the B16 model for melanoma (**Figure 8**).

Example 4 - ArgLong2-specific T cell clones recognize Arginase 1-expressing THP-1 cells

MATERIALS AND METHODS

Generation of ArgLong2-specific T cell clones

ArgLong2 clone cultures were generated from a T cell culture enriched for ArgLong2 specific cells following a standard rapid expansion protocol (REP): ArgLong2 specific cells were separated by magnetic bead sorting of TNF α producing T cells and used for limited dilution cloning in 96-well plates with ~1 cell/well. Each well contained 200 μ l of REP mix (irradiated feeder cells from 3 different buffy coats, α CD3 antibody and 6000U/ml IL-2) to promote the growth of ArgLong2-specific T cells.

Quantification of Arginase 1 mRNA in THP-1 cells by qPCR

THP-1 cells were stimulated with 20 ng/ml IL-13 (TriChem) for 48 hrs. Cells were harvested, washed in PBS and pelleted by centrifugation at 300 g for 5 minutes. The pellets were kept on ice, resuspended in 350 µl RLT Plus-Buffer (Qiagen). RNA was purified using the RNAeasy Kit (Qiagen) according to manufacturer's instruction with final elution in 30 µl of RNA-free water. The RNA concentration was measured on the NanoDrop 2000 Spectrophotometer (Thermo Scientific). RNA was stored at -80°C.

Total RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). For each reaction, 1000 ng RNA was reverse transcribed. For RT-qPCR, the cDNA was diluted 1:5 and subjected to RT-qPCR analysis using the TaqMan Gene Expression Assay on the Roche Lightcycler 480 Instrument. RT-qPCRs were run in quadruplicates and data was analysed using the ddCT-method with normalization to expression level of the house keeping gene *RPLPO* and control sample. For low concentration samples that were not amplified, Ct was set to 40. No-reverse transcriptase controls (cDNA reactions setup without reverse transcriptase) served as controls of specific amplification. Arg1 human primer was purchased from Thermofisher (undisclosed sequence, product number Hs00163660_m1).

Determination of THP-1 cell recognition by ArgLong2-specific T cells

Untreated and IL-4/IL-13-treated THP-1 cells were washed and divided into two groups: HLA-DR/DQ/DP blocking antibody (clone Tü39) was added to the first group at a concentration of 10 µg/ml for 20 min at 37 °C. The second group of THP-1 cells was left untreated. After 20 min HLA-II blocking THP-1 cells were washed. THP-1 cells treated with IL-4/IL-13 (with or without HLA-II block) were then mixed with ArgLong2 peptide specific T cells at effector:target ratio of 2:1 and then processed according to the standard intracellular cytokine staining protocol.

RESULTS

In order to further evaluate the functionality of ArgLong2-specific T cells, T cell clones have been generated from a healthy donor previously identified with a strong ArgLong2 response, and their ability to specifically recognise Arginase 1-expressing targets was examined.

Th2 cytokines, such as IL-4 or IL-13 are known to upregulate ARG1 expression in myeloid cells. To test whether ArgLong2-specific T cells would specifically recognise Th2 cytokine-treated myeloid cells, the ability of ArgLong2 T cell clones to recognise HLA-matched monocytic THP-1 cell line that was pre-stimulated 48 hours with either IL-4 (100U/ml) or IL-13 (20U/ml) was tested.

Th2-cytokine treated THP-1 showed increased expression of Arginase 1. In this regard, **Figure 9C** shows that Arginase 1 expression is induced in THP-1 cells when pre-treated with IL-13, thereby increasing presentation of Arginase 1-derived peptide epitopes on the surface of these cells.

ArgLong2-specific CD4 T cell clones were shown to recognise IL-4 and IL-13 treated THP-1 cells, as indicated by the increased production of TNF α and IFN γ against these cells compared to the untreated THP-1 (**Figure 9A**). Blocking of the HLA class II molecules abrogates the increased recognition of the IL-4 or IL-13 treated THP-1 cells, showing that increased recognition of the IL-4 and IL-13 treated THP-1 cells is dependent on the HLA class II presentation of ARG1 peptides. **Figure 9B** illustrates representative data from Figure 9A in dot plots format, showing the production of IFN γ and TNF α in response to IL-4 and IL-13 treated THP-1 cells without or with HLA class II blocking.

In a separate experiment, PBMCs from a healthy donor (HD22, known to have a pre-existing *ex vivo* response against ArgLong2) were treated with IL-4 (100 U/ml) or IL-13 (20 U/ml) for 7 days in order to increase presentation of the Arginase 1-derived peptides in the PBMC culture and thus stimulate the intrinsic ArgLong2 specific T cells present in the PBMCs. After 7 days of stimulation with IL-4 or IL-13, the PBMCs were analysed in IFN γ ELISPOT assay to check the changes in the frequency of the ArgLong2-specific T cells.

Increased ArgLong2 responses were seen in IL-4 and IL-13 treated PBMC cultures as compared to untreated control. The magnitude of the IL-13 stimulated ArgLong2 response was comparable with the responses seen after *in vitro* ArgLong2 peptide stimulation, suggesting a strong activation of Arginase 1-specific cells in the Th2 cytokine conditions.

SEQUENCES

SEQ ID NO	Sequence	Name	Start pos	End pos
1	ISAKDIVYIGLRDVPGEHYILKTLGIKYFSMTEVDRL	ArgLong2	169	206
2	ISAKDIVYIGLRDVPGEHYI I KTLGIKYFSMTEVD KL *	mArgLong2	169	206
3	ISAKDIVYIGLRDVPGEHYILKTLGIKYFSM	ArgLong3	169	200

4	ISAKDIVYIGLRDVPDGEHYII <u>I</u> KTLGIKYFSM*	mArgLong3	169	200
5	ISAKDIVYIGLRDVPDGEHYILKTLGIKYFSMTEVDRLGIGK	ArgLong	169	210
6	ISAKDIVYIGLRDVPDGEHYII <u>I</u> KTLGIKYFSMTEVD <u>K</u> LGIGK*	mArgLong	169	210
7	AKDIVYIGLRDVPDGEHYIL	Arg1-18	171	190
8	DVPDGEHYILKTLGIKYFSM	Arg1-19	181	200
9	KTLGIKYFSMTEVDRLGIGK	Arg1-20	191	210

* indicates a sequence from murine Arginase 1 which includes at least one difference relative to the corresponding region of human Arginase 1. Residues which are non-identical with the corresponding human sequence are bold and underlined.

5 Murine and human Arginase 1 are the same length so start and end positions are the same.

Full length human Arginase 1 (NP_000036.2) (SEQ ID NO: 10)

10 MSAKSRTIGI IGAPFSKGQP RGGVEEGPTV LRKAGLLEKL KEQECDVKDY GDLPFADIPN
 DSPFQIVKNP RSVGKASEQL AGKVAEVKK GRISLVLG GD HSLAIGSIG HARVHPDLGV
 IWDAHTDIN TPLTTTSGNL HGQPVSFLLK ELKGKIPDVP **GFSWVTPCIS AKDIVYIGLR**
DVPDGEHYIL KTLGIKYFSM TEVDRLGIGK VMEETLSYLL GRKKRPIHLS FDVDGLDPSF
 TPATGTPVVG GLTYREGLYI TEEIYKTGLL SGLDIMEVNP SLGKTPEEVT RTVNTAVAIT
 15 LACFGLAREG NHKPIDYLNPK

Region identified as a hotspot for immunogenicity shown bold and underlined

Full length murine Arginase 1 (NP_031508.1) (SEQ ID NO: 11)

20 MSSKPKSLEI IGAPFSKGQP RGGVEKGPA LRKAGLLEKL KETEDVDRDH GDIAFVDVPN
 DSSFQIVKNP RSVGKANEEL AGVVAEVQKN GRVSVVLGGD HSLAVGSISG HARVHPDLCP
 IWDAHTDIN TPLTTSSGNL HGQPVSFLLK ELKGKFPDVP **GFSWVTPCIS AKDIVYIGLR**
DVPDGEHYII KTLGIKYFSM TEVDKLGIGK VMEETFSYLL GRKKRPIHLS FDVDGLDPAF
 TPATGTPVLG GLSYREGLYI TEEIYKTGLL SGLDIMEVNP TLGKTAEVVK STVNTAVALT
 LACFGTQREG NHKPGTDYLYK PPK

25 *Region identified as a hotspot for immunogenicity shown bold and underlined*

Hotspot in human arginase 1 - positions 161-210 of SEQ ID NO: 10

GFSWVTPCISAKDIVYIGLRDVPDGEHYILKTLGIKYFSMTEVDRLGIGK (SEQ ID NO: 12)

30 *Hotspot in murine arginase 1 - positions 161-210 of SEQ ID NO: 11*

GFSWVTPCISAKDIVYIGLRDVPDGEHYII**I**KTLGIKYFSMTEVD**K**LGIGK (SEQ ID NO: 13)

Residues which are non-identical with the corresponding human sequence are bold and underlined.

CLAIMS

1. A polypeptide consisting of the amino acid sequence of SEQ ID NO: 1.
2. A polynucleotide encoding the polypeptide of claim 1.
3. A vector comprising the polynucleotide of claim 2.
4. The polypeptide of claim 1, in which the C terminal amino acid is replaced with the corresponding amide.
5. A composition comprising the polynucleotide of claim 2 and an adjuvant.
6. A composition comprising the polypeptide of claim 1 or 4, or the vector of claim 3, and an adjuvant.
7. A composition according to claim 6, comprising at least one pharmaceutically acceptable diluent, carrier or preservative.
8. A composition according to claim 6 or 7 wherein the adjuvant is selected from the group consisting of bacterial DNA based adjuvants, oil/surfactant based adjuvants, viral dsRNA based adjuvants, imidazoquinolines, and a Montanide ISA adjuvant.
9. The polypeptide of claim 1 or 4, the vector of claim 3, or the composition of any one of claims 6 to 8 for use in a method of treating or preventing a disease or condition in a subject, wherein said polypeptide or vector or said composition is to be administered to the subject.
10. The polypeptide, vector or composition for use according to claim 9 wherein the disease or condition is characterized at least in part by excessive immune suppressive function of an Arginase, and/or said wherein disease or condition is cancer.

11. The polypeptide, vector or composition for use according to claim 9 or 10 wherein the disease or condition is cancer and optionally wherein the polynucleotide, vector or composition is to be simultaneously or sequentially administered with an additional cancer therapy, preferably an antibody.

5

12. The polypeptide, vector or composition for use according to claim 10 or 11 wherein said cancer is breast, lung, colon or prostate cancer, or is a melanoma, or is a leukemia, preferably acute myeloid leukemia (AML).

10 13. A method of stimulating Arginase1-specific T cells, the method comprising contacting peripheral blood mononuclear cells (PBMCs) with the polypeptide of claim 1 or 4, the vector of claim 3, or the composition of any one of claims 6 to 8, wherein the method is performed *ex vivo*.

15 14. The method of claim 13, wherein the PBMCs are present in a sample taken from a healthy subject or from a cancer patient, optionally a tumour sample.

15 15. Use of the polypeptide of claim 1 or 4, the vector of claim 3 or the composition of any one of claims 6 to 8 in the manufacture of a medicament for the treatment or prevention of
20 cancer in a subject.

16. The use of claim 15, wherein the cancer is characterized at least in part by excessive immune suppressive function of an Arginase.

25 17. The use of claim 15 or 16, wherein an additional cancer therapy, preferably an antibody, is to be administered simultaneously or sequentially to the subject.

18. The use of claim 16 or 17, wherein said cancer is breast, lung, colon or prostate cancer, or is a melanoma, or is a leukemia, preferably acute myeloid leukemia (AML).

30